CL115,347, an analogue of prostaglandin E2. Peripheral circulatory effects of single ascending doses administered transdermally in normal subjects and in patients with Raynaud's phenomenon.
The beneficial effects of intra-arterial or intravenous infusion of the prostanoid products of anachridonic acid, PGE and prostacyclin (PGI2) are well documented. More recently an analogue of PGE2, (CL 115,347, American Cynamid Co.) has become available. This substance is absorbed transdermally from a patch placed on the skin. In a placebo-controlled trial the vasodilatory effect of single incremental dosage, 500 mcg, 1000 mcg and 1500 mcg, was measured in a temperature-/humidity controlled laboratory in normal subjects and in patients with primary and secondary Raynaud's phenomenon. The optimal dosage proved to be 1000 mcg; the effect may last for 84 hours; higher dosage may be associated with a "steal" phenomenon.
D000287:Administration, Topical; D000328:Adult; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D005385:Fingers / Q000098:blood supply; D006801:Humans; D008297:Male; D010991:Plethysmography; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage* / Q000494:pharmacology; D011928:Raynaud Disease / Q000188:drug therapy*; D012039:Regional Blood Flow / Q000187:drug effects
D011459:Prostaglandins E, Synthetic; D015232:Dinoprostone; C034232:viprostol